ImmunoGen Announces Webcast of Presentation at Upcoming SVB Leerink 10th Annual Global Healthcare ConferenceBusiness Wire • 02/11/21
ImmunoGen Announces Webcast of Presentation and Q&A at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/30/20
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual MeetingBusiness Wire • 12/05/20
ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid LeukemiaBusiness Wire • 11/30/20
ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual ConferencesBusiness Wire • 11/18/20
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare ConferenceBusiness Wire • 11/04/20
Earnings Preview: ImmunoGen (IMGN) Q3 Earnings Expected to DeclineZacks Investment Research • 10/30/20
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating ResultsBusiness Wire • 10/22/20
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater ChinaBusiness Wire • 10/19/20
ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market FacilityBusiness Wire • 10/12/20
ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell NeoplasmBusiness Wire • 10/05/20
ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMOBusiness Wire • 09/17/20